RecruitingPhase NA

The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males.

Renal Extraction of Glucagon and Renal Effects of Glucagon

Lead sponsor

Ali Asmar

Asset

Avexitide

Listed sites

Recruiting sites

Estimated enrollment

Study population

Chronic kidney disease

Eligibility highlights

•Male

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06498063

Org study IDH-22019483

Secondary ID20-1914; 21-1518Augustinus Fonden

Secondary IDNNF21OC0070308Novo Nordisk Fonden

Timeline

Milestones

Study start2024-02-20actual

Study first posted2024-07-12actual

Last update posted2024-07-12actual

Primary completion2025-03-28estimated

Study completion2025-07-31estimated

Assets

Investigational agents

Avexitide

Who this study enrolls

Chronic kidney disease

Who can enroll

Minimum age20 Years

Maximum age60 Years

SexMale

Healthy volunteersAccepted

Inclusion criteria

•Age: 20-60 years

•Normal health ascertained through questioning and medical examination

•Normal values for blood concentrations of fasting plasma glucose, fasting plasma total cholesterol, fasting triglycerides, HDL, LDL, creatinine, liver function, and electrolytes

•Informed consent

Exclusion criteria

•Immunosuppressive treatment in the preceding 12 months

•Alcohol abuse

•Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists, which, in the opinion of the investigator, may interfere with glucose metabolism

•Use of lithium

•Medical treatment that affects insulin secretion or cardiovascular performance measures

•Liver disease (ALT > 2x normal value)

•Renal impairment (se-creatinine > 130 μM and/or albuminuria)

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.